• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Parkinson's Disease with Intolerable Painful Dyskinesia: Standard Treatment and Subsequent Tips].

作者信息

Takeda Atsushi

机构信息

National Hospital Organization, Sendai-Nishitaga Hospital.

出版信息

Brain Nerve. 2022 May;74(5):468-473. doi: 10.11477/mf.1416202066.

DOI:10.11477/mf.1416202066
PMID:35589633
Abstract

The pathogenesis of pain related to dyskinesia in Parkinson disease is thought to be based on hypersensitivity to pain. To relieve symptoms, it is essential to reduce dyskinesia and alleviate symptoms. Frequent small doses of levodopa, dopamine agonists, MAOB inhibitors, and amantadine are effective. If improvement is insufficient, device-aided therapy should be considered. In addition, antidepressants, weak opioid analgesics, benzodiazepines, gabapentin, botulinum toxin injections, and exercise therapy are also worth trialing.

摘要

相似文献

1
[Parkinson's Disease with Intolerable Painful Dyskinesia: Standard Treatment and Subsequent Tips].
Brain Nerve. 2022 May;74(5):468-473. doi: 10.11477/mf.1416202066.
2
Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.缓释金刚烷胺(Gocovri)用于治疗帕金森病的运动障碍。
Med Lett Drugs Ther. 2017 Dec 4;59(1535):198-200.
3
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.金刚烷胺用于治疗GCH1基因突变复合杂合子中左旋多巴诱导的舞蹈症性运动障碍。
Mov Disord. 2004 Oct;19(10):1256-8. doi: 10.1002/mds.20194.
4
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).ADDS-5102(金刚烷胺)控释胶囊治疗帕金森病左旋多巴诱导运动障碍的随机、安慰剂对照试验(EASE LID 3)。
Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21.
5
The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.缓释金刚烷胺在帕金森病患者运动障碍治疗中的作用。
Neurodegener Dis Manag. 2018 Apr;8(2):73-80. doi: 10.2217/nmt-2018-0001. Epub 2018 Mar 22.
6
The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.金刚烷胺对帕金森病左旋多巴诱发异动症的影响:一项双盲、安慰剂对照研究。
Clin Neuropharmacol. 2000 Mar-Apr;23(2):82-5. doi: 10.1097/00002826-200003000-00004.
7
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).金刚烷胺缓释剂治疗帕金森病左旋多巴诱导的异动症(EASED研究)。
Mov Disord. 2015 May;30(6):788-95. doi: 10.1002/mds.26159. Epub 2015 Feb 4.
8
Extended-Release Amantadine for Levodopa-Induced Dyskinesia.盐酸安他非命缓释片治疗左旋多巴诱发的异动症
Expert Rev Neurother. 2019 Apr;19(4):293-299. doi: 10.1080/14737175.2019.1592677. Epub 2019 Mar 20.
9
Amantadine's role in the treatment of levodopa-induced dyskinesia.金刚烷胺在治疗左旋多巴诱发的异动症中的作用。
Neurology. 2014 Jan 28;82(4):288-9. doi: 10.1212/WNL.0000000000000068. Epub 2013 Dec 26.
10
Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.帕金森病中的左旋多巴诱导的运动障碍:流行病学、病因及治疗
Curr Neurol Neurosci Rep. 2007 Jul;7(4):302-10. doi: 10.1007/s11910-007-0046-y.